At irregular intervals, usually of a few decades, a new influenza virus emerges which is novel to all or most people which means that there can be little specific immunity among humans except for older people who may have met unless they met the same virus. This new virus can then spread rapidly from human to humans all over the world. Because of the lack of human immunity the virus is often more aggressive and causes more serious disease and deaths.
At least some of the three pandemics during the last (20th) century are thought to have come from an animal or bird influenza virus that itself mutated or swapped genes with a human (so called recombination) and acquired the ability to both infect humans and, more importantly, spread between them. It is thought that as an animal/bird influenza adapts to humans and becomes transmissible, it also loses some of its pathogenicity for humans. This is of evolutionary value as the new strain is more likely to survive if it does not kill its new human host.
Eventually as immunity increases among humans, and the pandemic virus changes, the pandemic strain becomes part of (and tends to dominates) the mix of seasonal influenza viruses.
Related documents
Review of ECDC’s response to the influenza pandemic 2009/10 (November 2011)
Technical report: Pandemic influenza preparedness in the EU/EEA 2007 (Annex 1, Annex 2, Annex 3)
Report for policy makers: Pandemic Preparedness in the European Union 2007
Influenza Surveillance in a Pandemic (Paper from ECDC working group, August 2007)
Special Report: Innovations in EU pandemic preparedness, September 2007
Technical report: Pandemic influenza preparedness in the EU 2006
Third joint EC/ECDC/WHO Workshop on Pandemic Influenza Preparedness (May 2006)
|
|
|
Weekly influenza surveillance overview week 19: influenza season is coming to its end in Europe 17 May 2012 Weekly influenza surveillance overview week 18: influenza season coming to its end in Europe 11 May 2012 High standard of influenza virus detection and typing maintained across influenza reference laboratories in EU/EEA 08 May 2012 |
|
|
|
|
Communicable disease threats report, 13-19 May 2012, week 20 21 May 2012 Weekly influenza surveillance overview, 17 May 2012 - week 19 17 May 2012 Weekly influenza surveillance overview, 11 May 2012 - week 18 11 May 2012 |
|
|
|
|
Reproducibility of serology assays for influenza A(H1N1)2009pdm 23 Apr 2012 Association of childhood narcolepsy and cataplexy and receipt of a pandemic influenza vaccine in Finland in 2009-10 – First papers in a peer review journal 30 Mar 2012 Ferrets as experimental models of influenza in humans 07 Mar 2012 |
|
|
|
|
Report on the association between the 2009 pandemic vaccine (Pandemrix®) and narcolepsy – Republic of Ireland 19 Apr 2012 Lower than usual: early influenza vaccine effectiveness in parts of Europe in season 2011/12 13 Apr 2012 Controversial research on modifying A(H5N1) influenza viruses in the laboratory 04 Apr 2012 |
|
|
|
|
Second Joint ECDC/WHO Europe influenza meeting 06 Mar 2012 Training workshop on vaccine safety for Member States, building on the experience obtained in the ECDC vaccine safety project VAESCO 20 Feb 2012 |
|
|
|
|
|
|